Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of a range of oral SP-333
doses for the treatment of opioid-induced constipation (OIC) in adults with non-cancer pain
taking opioids.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc. Synergy Pharmaceuticals Inc.